Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionConjugate of 4 copies of ranpirnase, an amphibian ribonuclease, and hRS7, a humanized antibody against TROP-2, generated via the dock and lock (DNL) method
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsTreat breast cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today